# PERRIGO Co plc (PRGO)

Informational only - not investment advice.

CIK: 0001585364
SIC: 2834 Pharmaceutical Preparations
SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2834 Pharmaceutical Preparations](/industry/2834/)
Latest 10-K filed: 2026-02-26
SEC page: https://www.sec.gov/edgar/browse/?CIK=1585364
Filing source: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000009/prgo-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-26 · accession 0001585364-26-000009 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001585364.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 4,253,100,000 USD | 2025 | verified |
| Net income | -1,425,400,000 USD | 2025 | verified |
| Assets | 8,535,200,000 USD | 2025 | verified |
| Free cash flow | 145,100,000 USD | 2025 | computed |
| Net margin | -33.51% | 2025 | computed |
| Operating margin | -26.39% | 2025 | computed |
| Revenue YoY | -2.75% | 2025 | computed |
| ROE | -48.56% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | PRGO | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -33.5% | 1.0% | 26 | 107 |
| Operating margin | -26.4% | -1.3% | 32 | 100 |
| Revenue growth | -2.8% | 14.7% | 23 | 127 |
| FCF margin | 3.4% | -14.0% | 59 | 127 |
| ROE | -48.6% | -30.7% | 28 | 171 |
| ROA | -16.7% | -21.8% | 55 | 187 |
| Liabilities / equity | 1.91 | 0.38 | 80 | 173 |
| Current ratio | 2.76 | 4.89 | 27 | 188 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2834 Pharmaceutical Preparations, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 4253100000 | USD | 2025 | 2026-02-26 |
| Net income | -1425400000 | USD | 2025 | 2026-02-26 |
| Assets | 8535200000 | USD | 2025 | 2026-02-26 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-26. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001585364.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 5,280,600,000 | 4,946,200,000 | 4,731,700,000 | 3,869,900,000 | 4,088,200,000 | 4,138,700,000 | 4,451,600,000 | 4,655,600,000 | 4,373,400,000 | 4,253,100,000 |
| Net income | -4,012,800,000 | 119,600,000 | 131,000,000 | 146,100,000 | -162,600,000 | -68,900,000 | -140,600,000 | -12,700,000 | -171,800,000 | -1,425,400,000 |
| Operating income | -1,999,700,000 | 598,200,000 | 236,500,000 | 174,700,000 | 265,200,000 | 410,400,000 | 78,900,000 | 151,900,000 | 112,900,000 | -1,122,200,000 |
| Gross profit | 2,051,800,000 | 1,979,500,000 | 1,831,500,000 | 1,433,700,000 | 1,494,900,000 | 1,416,200,000 | 1,455,400,000 | 1,680,400,000 | 1,542,700,000 | 1,494,500,000 |
| Diluted EPS | -28.01 | 0.84 | 0.95 | 1.07 | -1.19 | -0.52 | -1.04 | -0.09 | -1.25 | -10.29 |
| Operating cash flow | 654,900,000 | 698,900,000 | 593,000,000 | 387,800,000 | 636,200,000 | 156,300,000 | 307,300,000 | 405,500,000 | 362,900,000 | 238,500,000 |
| Capital expenditures | 106,200,000 | 88,600,000 | 102,600,000 | 137,700,000 | 170,400,000 | 152,100,000 | 96,400,000 | 101,700,000 | 118,300,000 | 93,400,000 |
| Dividends paid | 83,200,000 | 91,100,000 | 104,900,000 | 112,400,000 | 123,900,000 | 129,600,000 | 142,400,000 | 149,700,000 | 152,500,000 | 159,300,000 |
| Assets | 13,870,100,000 | 11,628,800,000 | 10,983,400,000 | 11,301,400,000 | 11,488,400,000 | 10,425,700,000 | 11,017,300,000 | 10,809,100,000 | 9,647,700,000 | 8,535,200,000 |
| Liabilities | 7,912,500,000 | 5,458,200,000 | 5,315,300,000 | 5,497,300,000 | 5,833,300,000 | 5,274,000,000 | 6,175,200,000 | 6,041,200,000 | 5,328,300,000 | 5,599,700,000 |
| Stockholders' equity | 5,958,100,000 | 6,170,500,000 | 5,668,000,000 | 5,803,800,000 | 5,655,100,000 | 5,151,700,000 | 4,842,100,000 | 4,767,900,000 | 4,319,400,000 | 2,935,500,000 |
| Free cash flow | 548,700,000 | 610,300,000 | 490,400,000 | 250,100,000 | 465,800,000 | 4,200,000 | 210,900,000 | 303,800,000 | 244,600,000 | 145,100,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | -75.99% | 2.42% | 2.77% | 3.78% | -3.98% | -1.66% | -3.16% | -0.27% | -3.93% | -33.51% |
| Operating margin | -37.87% | 12.09% | 5.00% | 4.51% | 6.49% | 9.92% | 1.77% | 3.26% | 2.58% | -26.39% |
| Return on equity | -67.35% | 1.94% | 2.31% | 2.52% | -2.88% | -1.34% | -2.90% | -0.27% | -3.98% | -48.56% |
| Return on assets | -28.93% | 1.03% | 1.19% | 1.29% | -1.42% | -0.66% | -1.28% | -0.12% | -1.78% | -16.70% |
| Liabilities / equity | 1.33 | 0.88 | 0.94 | 0.95 | 1.03 | 1.02 | 1.28 | 1.27 | 1.23 | 1.91 |
| Current ratio | 1.53 | 1.96 | 1.89 | 2.04 | 2.27 | 2.43 | 2.44 | 1.79 | 2.38 | 2.76 |

## As-reported value updates

6 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/PRGO/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001585364.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-10-01 |  |  | -0.37 | reported discrete quarter |
| 2023-Q1 | 2023-04-01 |  |  | -0.02 | reported discrete quarter |
| 2023-Q2 | 2023-07-01 |  |  | 0.06 | reported discrete quarter |
| 2023-Q3 | 2023-07-01 |  | 8,400,000 |  | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 1,123,800,000 |  | 0.10 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 1,156,900,000 | -32,300,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-30 | 1,082,100,000 | 2,000,000 | 0.01 | reported discrete quarter |
| 2024-Q2 | 2024-03-30 |  | 2,000,000 |  | reported discrete quarter |
| 2024-Q2 | 2024-06-29 | 1,065,500,000 |  | -0.79 | reported discrete quarter |
| 2024-Q3 | 2024-06-29 |  | -108,400,000 |  | reported discrete quarter |
| 2024-Q3 | 2024-09-28 | 1,087,500,000 |  | -0.15 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 1,138,300,000 | -44,500,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-29 | 1,043,900,000 | -6,400,000 | -0.05 | reported discrete quarter |
| 2025-Q2 | 2025-03-29 |  | -6,400,000 |  | reported discrete quarter |
| 2025-Q2 | 2025-06-28 | 1,056,300,000 |  | -0.06 | reported discrete quarter |
| 2025-Q3 | 2025-06-28 |  | -8,400,000 |  | reported discrete quarter |
| 2025-Q3 | 2025-09-27 | 1,043,300,000 |  | 0.05 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 1,109,600,000 | -1,418,100,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-28 | 969,200,000 | -398,600,000 | -2.87 | reported discrete quarter |
| 2026-Q2 | 2026-03-28 |  | -398,600,000 |  | reported discrete quarter |
| 2026-Q2 | 2026-06-27 | 1,022,800,000 |  | 0.53 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from PRGO's latest 10-K: [/company/PRGO/business/](/company/PRGO/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from PRGO's latest 10-K: [/company/PRGO/risk-factors/](/company/PRGO/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000145/prgo-20260627.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-05
Report date: 2026-06-27

ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis (“MD&A”) is intended to provide readers with an understanding of our financial condition, results of operations, and cash flows by focusing on changes in certain key measures from year to year. This MD&A is provided as a supplement to, and should be read in conjunction with our Condensed Consolidated Financial Statements and accompanying Notes found in Item 1 included in this Form 10-Q, and our Form 10-K for the year ended December 31, 2025 (the “2025 Form 10-K”). These historical financial statements may not be indicative of our future performance. This discussion contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks referred to under “Risk Factors” in Item 1A of our 2025 Form 10-K and Part II. Item 1A of this Form 10-Q.

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc (“Elan”). Unless the context requires otherwise, the terms Perrigo, the “Company,” “we,” “our,” “us,” and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

EXECUTIVE OVERVIEW

Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter (“OTC”) self-care market, Perrigo is led by its vision “To Provide The Best Self-Care For Everyone” and its purpose to “Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All”.

Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for:

•Access: Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness.

•Value: Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions.

•Reliability: Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers.

Perrigo provides access to trusted self-care solutions that can be used without the need to visit a health practitioner for a prescription. Guided by our vision and purpose, our strategic goal is to create sustainable and value accretive growth by 1) delivering consumer preferred brands and innovation, 2) driving category growth with our customers, 3) powering our business with our world-class, quality assured supply chain, including a focus on sustainability with meaningful goals to reduce greenhouse gas emissions, water, and waste, in addition to increasing the recyclability of our packaging, and 4) evolving our global organization to one cohesive operating model. Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.

Perrigo's broad offerings are well diversified across several major product categories as well as across geographies, primarily in North America and Europe, with no one product representing more than 5% of total revenue. In North America, Perrigo is the leading store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, in addition to offering brands including Opill® and Mederma®. In Europe, our portfolio consists primarily of brands, including Compeed®, ellaOne®, Solpadeine®, and Jungle Formula®.

Perrigo’s unique portfolio of businesses complement each other, where 1) store brands generate cash for investments into the Company’s key higher margin, higher growth brands, 2) branding and innovation capabilities are leveraged for both brand and store brand demand generation designed to generate stronger customer partnerships, 3) consumer-led innovation is scaled across brands, store brands and geographies, and 4) leveraging the scale of our global supply chain with more molecules at more price points to more consumers to drive increased household penetration.

36

Perrigo Company plc - Item 2

Executive Overview

The Company’s plan to drive increased cash flow and total shareholder return is anchored in its ‘Three-S’ plan – ‘Stabilizing,’ ‘Streamlining,’ and ‘Strengthening’ our business. This process centers on restoring consistency in our core business, streamlining our cost structure and building capabilities that support scalable long-term growth.

Our fiscal year begins on January 1 and ends on December 31. We end our quarterly accounting periods on the Saturday closest to the end of the calendar quarter, with the fourth quarter ending on December 31 of each year.

Our Segments

Our reporting and operating segments reflect the way our chief operating decision maker, who is our Interim Chief Executive Officer (“CEO”), makes operating decisions, allocates resources and manages the growth and profitability of the Company. Our reporting segments are:

•Self Care includes over-the-counter health and wellness products intended for consumer self-treatment of common conditions, such as pain & sleep, upper respiratory, digestive health and healthy lifestyle products including vitamins, minerals and supplements ("VMS") and oral electrolyte beverages.

•Specialty Care includes branded and specialty consumer health products that address more targeted or complex self-care needs, including women's health and skin health offerings, such as skin healing and insect repellant.

•Infant Formula is comprised of the infant formula product category, which includes nutrition products designed to meet the dietary needs of infants.

The Company's Oral Care product category and Other product category, which includes the Dermacosmetics business (through its April 30, 2026 divestment), are together disclosed as “All Other.”

We previously operated an Rx segment consisting of our U.S. generic prescription pharmaceuticals business and other pharmaceuticals and diagnostic businesses in Israel, which have been divested. The Rx segment was reported as Discontinued Operations in 2021, and is presented as such for all periods in this report. See Item 1. Note 4 for more information.

Products

We offer products in the following categories:

[[GREPCENT_TABLE]]
[["Reporting Segment","Product Category","","Description"],["Self Care","Upper Respiratory","","Products that relieve upper respiratory symptoms, including cough suppressants, expectorants, sinus and allergy relief."],["Digestive Health","","Products such as antacids, anti-diarrheal, and anti-heartburn that relieve symptoms associated with digestive issues."],["Healthy Lifestyle","","Products that help consumers live a healthy lifestyle such as smoking cessation, weight management, heart health, VMS, nutraceutical and electrolytes."],["Pain and Sleep-Aids","","Products comprised of pain relievers, fever reducers and sleep-aids."],["Specialty Care","Skin Health","","Products for the face and body such as scar management, lice treatment, insect repellant and other products for various skin conditions."],["Women's Health","","Women's health products, including feminine hygiene and contraceptives."],["Infant Formula","Infant Formula","","Infant nutrition products designed to meet dietary needs."],["All Other","Oral Care","","Products used for oral care, including toothbrushes, toothbrush replacement heads, floss, flossers, whitening products and toothbrush covers."],["Other(1)","","Other miscellaneous self-care products, including the Dermacosmetics business."]]
[[/GREPCENT_TABLE]]

(1) The Dermacosmetics business was historically reported in the Skin Care category and is now included within Other through its April 30, 2026 divestment.

37

Perrigo Company plc - Item 2

Executive Overview

Recent Developments

•On April 30, 2026, the sale of the Dermacosmetics Business was completed for total consideration of $362.9 million, net of cash delivered. The transaction consists of €305.6 million or $358.5 million in upfront cash, $6.2 million of proceeds received for inventory on hand, less $1.8 million of cash delivered. The transaction also stipulates up to an additional €27.0 million contingent on the achievement of net sales milestones, of which €18.0 million is remaining through 2027. The sale resulted in a pre-tax gain of $129.5 million during the quarter. Brands sold in the transaction include ACO, Biodermal, and Iwostin.

•On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors of the Company. Concurrently, the Board appointed Albert A. Manzone, Director and member of the Audit Committee of the Board, as the Company’s Interim President and Chief Executive Officer.

•On June 30, 2026, the Board of Directors of the Company appointed Salman Amin and Omer Gajial to serve as members of the Board effective as of June 30, 2026. In connection with the appointments, the Board increased the size of the Board from 8 to 10.

Restructuring

Supply Chain Reinvention Program

In 2022, we initiated a Supply Chain Reinvention Program to reduce structural costs, improve profitability and our service levels to our retail partners, and strengthen our resiliency by streamlining and simplifying our global supply chain. Through this initiative, we have reduced portfolio complexity, invested in advanced planning capabilities, diversified sourcing, and optimized our manufacturing assets and distribution models. The program objectives are now realized with approximately $157 million of annualized benefits (not including related depreciation expense on capital investments) achieved by the end of fiscal year 2025. Total costs incurred over the same period including capital investments, restructuring expenses and implementation costs totaled approximately $286 million. For the remaining project wind-down activities, we anticipate less than $10 million of additional costs to be incurred through fiscal year 2026. Refer to Item 1. Note 14 for further details on restructuring charges.

Project Energize

As part of our sustainable, value accretive growth strategy, we launched Project Energize in the first quarter of 2024 - a global investment and efficiency program to drive the next evolution of capabilities and organizational agility. This three-year program was expected to produce significant benefits in our long-term business performance by enabling our One Perrigo growth strategy, increasing organizational agility and mitigating impacts from stabilizing and strengthening the infant formula business. As of December 31, 2025, Project Energize had achieved these objectives and has substantively completed.

Project Energize delivered approximately $167 million of annualized pre-tax savings as of the end of the fiscal year 2025, within the range of $140 million to $170 million expected by the end of 2026. Reinvestment savings were $35 million over the same period. Restructuring and related charges associated with these actions were approximately $138 million over the same period compared to an original estimated range of $140 million to $160 million. For the remaining project wind-down activities, we anticipate less than $10 million of additional costs to be incurred through fiscal year 2026. Refer to Item 1. Note 14 for further details on restructuring charges.

Nutrition Network Optimization; Strategic Review

In 2025, we initiated the Nutrition Network Optimization project to optimize our infant formula manufactu

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000009/prgo-20251231.htm
Complete FY 2025 MD&A: /company/PRGO/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-26
Report date: 2025-12-31

ITEM 7.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013 and became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"). Unless the context requires otherwise, the terms "Perrigo," the "Company," "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries.

The following Management's Discussion and Analysis ("MD&A") is intended to provide readers with an understanding of our financial condition, results of operations, and cash flows by focusing on changes in certain key measures from year to year. This MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and accompanying Notes found in Item 8 of this report. See also "Cautionary Note Regarding Forward-Looking Statements." This discussion and analysis compares 2025 results to 2024. For discussion and analysis that compares 2024 results to 2023, see Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in Part II of our Annual Report on Form 10-K for the year ended December 31, 2024.

EXECUTIVE OVERVIEW

Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All".

Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for:

•Access: Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness.

•Value: Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions.

•Reliability: Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers.

Perrigo provides access to trusted self-care solutions that can be used without the need to visit a health practitioner for a prescription. Guided by our vision and purpose, our strategic goal is to create sustainable and value accretive growth by 1) delivering consumer preferred brands and innovation, 2) driving category growth with our customers, 3) powering our business with our world-class, quality assured supply chain, including a focus on sustainability with meaningful goals to reduce greenhouse gas emissions, water, and waste, in addition to increasing the recyclability of our packaging, and 4) evolving our global organization to one cohesive operating model. Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.

Perrigo's broad offerings are well diversified across several major product categories as well as across geographies, primarily in North America and Europe, with no one product representing more than 5% of total revenue. In North America, Perrigo is the leading store brand private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill® and Mederma®. In Europe, our portfolio consists primarily of brands, including Compeed®, ellaOne®, Solpadeine®, Jungle Formula®, and ACO®.

Two key initiatives have been fundamental in advancing our self-care strategy — our Supply Chain Reinvention Program, a global supply chain efficiency program, and Project Energize, a global investment and efficiency program. In addition, we continue to invest in other initiatives, including innovation, information systems and tools, and our people to drive consistent and sustainable results.

Perrigo’s unique complementary businesses enable each individually to play a specific reinforcing role, where 1) store brands generate cash for investments into the Company’s key higher margin, higher growth brands, 2) branding and innovation capabilities deliver both brand and store brand demand generation designed to lead to stronger customer partnerships, 3) consumer-led innovation scaled across brands, store brands and geographies, and 4) leveraging global supply chain scale of more molecules at more price points to more consumers driving household penetration.

37

Perrigo Company plc - Item 7

Executive Overview

The Company’s plan to drive cash flow and total shareholder return is anchored behind its ‘Three-S’ plan – ‘Stabilizing’ Consumer Self-Care Americas store brand and infant formula businesses; ‘Streamlining’ the global portfolio, enterprise operating model and Consumer Self-Care International business; and ‘Strengthening’ what is working by prioritizing and increasing investments behind key brands.

Our fiscal year begins on January 1 and ends on December 31. We end our quarterly accounting periods on the Saturday closest to the end of the calendar quarter, with the fourth quarter ending on December 31 of each year.

Our Segments

Our reporting and operating segments reflect the way our chief operating decision maker, who is our Chief Executive Officer ("CEO"), makes operating decisions, allocates resources and manages the growth and profitability of the Company. Our reporting and operating segments are:

•Consumer Self-Care Americas ("CSCA") comprises our consumer self-care business in the U.S. and Canada.

•Consumer Self-Care International ("CSCI") comprises our consumer self-care business outside of the U.S. and Canada, primarily in Europe and Australia.

For information on each segment, our business environment, and competitive landscape, refer to Item 1. Business. For results by segment and geographic locations see below Segment Results and Item 8. Note 2 and Note 21.

Recent Developments

Segment Change

During the first quarter of 2026, we have begun transitioning from a geographic segment reporting structure to a category-based segment view, enabling us to better align our financial disclosures and operational analysis with our product offerings and strategic priorities. The change is being made to stay in alignment with the way our chief operating decision maker intends to make future operating decisions, allocate resources and manage the growth and profitability of the Company. The anticipated change is not expected to have any impact on the Company's historical consolidated financial position, results of operations, or cash flows.

Market Factors and Trends

Macroeconomic Uncertainty

Current macroeconomic conditions remain dynamic, including impacts from inflation and interest rates, volatile changes in foreign currency exchange rates, tariffs and other trade restrictions, political unrest and uncertainty and legislative and regulatory changes. Any causes of market size contraction could reduce our sales or erode our operating margin and consequently reduce our net earnings and cash flows. As a result of these dynamic conditions and uncertainties, we have modified, and may further modify, our operations and strategic initiatives, including by adjusting our investment priorities, reallocating resources, or delaying specific initiatives, such as deferring capital expenditures on the Nutrition Network Optimization project, initiating an enterprise-wide operational enhancement program, and seeking further working capital improvements.

Continuing uncertainties arising from increased tariffs on imported products could have an adverse effect on our Company. In 2025, the U.S. government announced new or additional tariffs on products imported from many countries and individualized "reciprocal" tariffs on countries with which the U.S. has the largest trade deficits. While some tariffs have become effective, others have been temporarily suspended, increased then reduced or permanently repealed. The U.S. government has announced trade agreements with various governments as well as additional tariffs on countries due to geo-political issues. As a result, there continues to be significant volatility and uncertainty regarding the scope, timing, implementation and effective rates of tariffs.

Based on current assessments, and excluding any potential impact from future pharmaceutical tariffs that may cover ingredients used in the manufacturing of OTC products, we estimate a gross increase to global cost of goods sold of approximately $30 million to $40 million, on a full-year basis beginning in 2026, updated from the previously estimated range of $50 million to $60 million. We continue to mitigate these impacts through a combination of strategic pricing actions, insourcing to our U.S.-based manufacturing facilities and other supply chain actions.

In addition, our interest expense is impacted by the overall global economic and interest rate environment. We manage interest rate risk through our capital structure and the use of interest rate swaps to fix the interest rate on greater than 90% of our outstanding debt.

38

Perrigo Company plc - Item 7

Executive Overview

War in Ukraine

The invasion of Ukraine by Russia and resulting economic and political sanctions imposed by the United States, United Kingdom, European Union, and other countries on Russia, Belarus, and occupied regions in Ukraine have negatively impacted our results from operations in the region. Future impacts are difficult to predict due to the high level of uncertainty related to the war’s duration, evolution and resolution. If the conflict spreads or materially escalates, or economic conditions deteriorate, the impact on our business and results of operations could be material.

Middle East Conflicts

We continue to closely monitor the ongoing conflict and the social, political and economic environment in Israel and in the broader Middle East to evaluate the impacts on our operations and supply chain. Israel is a global technology research and development center that plays a critical role in the global Active Pharmaceutical Ingredients ("API") market, as a number of our key suppliers are located within Israel. The Company sources some raw materials and finished goods from suppliers in Israel for certain self-care products, including omeprazole. To date, Perrigo has confirmed that our suppliers in the region have active operations and continue to manufacture materials for us, and we have not received any reports of restrictions on imports or exports in Israel. However, there is potential for some disruption as it relates to in-country logistics, including freight. As a precaution, Perrigo has engaged alternate suppliers to help minimize a potential supply disruption. If the conflict spreads or materially escalates, or if the conflict leads to further volatility and uncertainty in financial markets or economic conditions, the impact on our business and results of operations could be material. For example, an escalation in military activity in the Red Sea region has the potential to disrupt supply chains and lead to further inflationary pressures which we are also continuing to monitor.

Inflationary Costs and Supply Chain

Supply chain disruptions continue in specific categories such as agricultural commodities due to climate impacts, and supply chain shortages, the conflicts between Russia and Ukraine, the Middle East Conflict and geopolitical tensions. Inflationary pressures are still a factor on cost in major economies globally across food, energy and labor. While global inflation is expected to fall, U.S. inflation is now predicted to

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/PRGO/mda/fy2025/
All MD&A years: /company/PRGO/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/PRGO/mda/fy2024/): filed 2025-02-28; accession 0001585364-25-000014 (https://www.sec.gov/Archives/edgar/data/1585364/000158536425000014/prgo-20241231.htm)
- [FY 2023 MD&A](/company/PRGO/mda/fy2023/): filed 2024-02-27; accession 0001585364-24-000009 (https://www.sec.gov/Archives/edgar/data/1585364/000158536424000009/prgo-20231231.htm)
- [FY 2022 MD&A](/company/PRGO/mda/fy2022/): filed 2023-02-28; accession 0001585364-23-000006 (https://www.sec.gov/Archives/edgar/data/1585364/000158536423000006/prgo-20221231.htm)
- [FY 2021 MD&A](/company/PRGO/mda/fy2021/): filed 2022-03-01; accession 0001585364-22-000011 (https://www.sec.gov/Archives/edgar/data/1585364/000158536422000011/prgo-20211231.htm)


## FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

| FDA-listed trade name | Active ingredient | Application | Original approval |
| --- | --- | --- | --- |
| DESLORATADINE | DESLORATADINE | [ANDA078361](/drug/anda-078361/) | 2011-12-22 |
| FAMOTIDINE | FAMOTIDINE | [ANDA075400](/drug/anda-075400/) | 2005-03-18 |
| LORATADINE | LORATADINE | [ANDA075728](/drug/anda-075728/) | 2004-08-20 |
| LORATADINE | LORATADINE | [ANDA076301](/drug/anda-076301/) | 2004-06-25 |
| LORATADINE | LORATADINE | [NDA021512](/drug/nda-021512/) | 2004-06-24 |
| MICONAZOLE 3 COMBINATION PACK | MICONAZOLE NITRATE | [ANDA076357](/drug/anda-076357/) | 2004-03-30 |
| NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE | NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE | [ANDA076518](/drug/anda-076518/) | 2004-03-17 |
| IBUPROFEN | IBUPROFEN | [ANDA076359](/drug/anda-076359/) | 2004-01-16 |
| IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE | IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE | [ANDA076478](/drug/anda-076478/) | 2003-11-05 |
| FAMOTIDINE | FAMOTIDINE | [ANDA075715](/drug/anda-075715/) | 2003-08-22 |
| RANITIDINE HYDROCHLORIDE | RANITIDINE HYDROCHLORIDE | [ANDA076195](/drug/anda-076195/) | 2002-08-30 |
| LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | LOPERAMIDE HYDROCHLORIDE; SIMETHICONE | [ANDA076029](/drug/anda-076029/) | 2002-08-30 |
| IBUPROFEN | IBUPROFEN | [ANDA075995](/drug/anda-075995/) | 2002-03-14 |
| KETOPROFEN | KETOPROFEN | [ANDA075364](/drug/anda-075364/) | 2002-02-07 |
| CROMOLYN SODIUM | CROMOLYN SODIUM | [ANDA075427](/drug/anda-075427/) | 2001-12-12 |

All 32 approved applications for PRGO: /drug/#PRGO

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.


## Macro cross-references

Indicators mapped to this company's SIC classification (industry 2834 Pharmaceutical Preparations) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/PRGO.md · JSON record: /company/PRGO.json · verified financials: /company/PRGO/financials.json / /company/PRGO/financials.csv · machine TOC for the whole site: /llms.txt